GlucoTrack (GCTK) AI Stock Analysis

• Market Cap: $3.48M
• Dividend Yield: N/A
• Average Volume (3M): 2.54M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.99
• Revenue Growth: N/A
• EPS Growth: 60.83%
• Country: US
• Employees: 11
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -4.64
• Shares Outstanding: 910,688
• 10 Day Avg. Volume: 100,775
• 30 Day Avg. Volume: 2,541,249
• PEG Ratio: -0.03
• Price to Book (P/B): -12.81
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.22
• Enterprise Value/Market Cap: -1.82
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 147.00
• Enterprise Value/Ebitda: 0.25
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $3.50 ▼(-9.56% Downside)

The score is held down primarily by extremely weak financial performance (minimal revenue, widening losses, heavy cash burn, and negative equity) and bearish technicals (below key moving averages with negative MACD). Valuation offers limited support due to ongoing losses and no dividend, while recent financing provides some near-term capital relief but does not offset the underlying fundamentals.

Positive Factors

Strategic Partnerships

The partnership with OneTwo Analytics aims to leverage AI-driven insights, potentially enhancing the performance and clinical value of GlucoTrack's monitoring devices, which could improve market adoption and user engagement.

Clinical Advancements

Successful clinical trials and ISO certification enhance GlucoTrack's credibility and readiness for market expansion, potentially increasing its competitive edge in the diabetes care industry.

Industry Collaboration

Participation in the EU-funded bionic pancreas initiative positions GlucoTrack at the forefront of innovative diabetes management solutions, potentially expanding its influence and market reach.

Negative Factors

Financial Instability

Negative equity and high financial instability indicate a precarious financial position, potentially limiting GlucoTrack's ability to invest in growth and innovation without external financing.

Lack of Revenue

The absence of revenue generation since 2020 underscores operational challenges and raises concerns about the company's ability to achieve sustainable growth and profitability.

Cash Flow Deficits

Persistent negative cash flow highlights ongoing cash burn, which may strain GlucoTrack's financial resources and hinder its ability to fund operations and strategic initiatives.

GlucoTrack Business Overview & Revenue Model

Company Description

GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.

How the Company Makes Money

GlucoTrack generates revenue primarily through the sale of its non-invasive glucose monitoring devices. The company's key revenue streams include direct sales of its products to consumers and healthcare providers, as well as potential licensing agreements and partnerships with other medical device companies or healthcare institutions. Additionally, GlucoTrack may explore subscription-based models for device usage and data management services, providing a recurring revenue stream. Strategic partnerships with diabetes care organizations and healthcare providers can also contribute to its earnings by expanding the market reach and adoption of its technology.

GlucoTrack Financial Statement Overview

Summary

GlucoTrack faces substantial financial challenges, characterized by a lack of revenue, negative equity, and persistent cash flow deficits. While recent financing activities have temporarily bolstered cash reserves, the lack of operational revenue and continuous losses highlight significant uncertainty about future financial stability and growth potential.

Income Statement

The company has not generated any revenue since 2020, indicating significant challenges in its operations or market conditions. The net income for 2024 shows a positive figure, but this is due to adjustments or one-off events rather than operational profitability, as EBIT and EBITDA remain negative historically.

Balance Sheet

The balance sheet reveals high financial instability with negative stockholders' equity in recent years, reflecting an excess of liabilities over assets. The debt-to-equity ratio cannot be calculated due to negative equity, presenting a concerning financial structure. Cash reserves have improved, but the equity ratio remains unfavorable, signaling potential risks.

Cash Flow

While operating cash flow is consistently negative, the company has managed to maintain liquidity through significant financing activities, as seen in 2024. The free cash flow remains heavily negative, indicating ongoing cash burn, but the influx of financing cash suggests some ability to support operations in the short term.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-43.00K	-36.00K	-13.00K	-23.00K	0.00	-47.00K
EBITDA	-24.88M	-21.98M	-7.08M	-4.41M	-3.94M	-2.65M
Net Income	-26.77M	-22.60M	-7.10M	-4.43M	-4.07M	-2.70M
Balance Sheet
Total Assets	10.21M	5.93M	4.91M	2.44M	6.26M	10.61M
Cash, Cash Equivalents and Short-Term Investments	9.55M	5.62M	4.49M	2.31M	6.06M	9.82M
Total Debt	267.00K	267.00K	196.00K	195.00K	250.00K	363.00K
Total Liabilities	3.33M	18.93M	1.71M	1.21M	1.11M	1.62M
Stockholders Equity	6.88M	-13.00M	3.20M	1.23M	5.16M	8.98M
Cash Flow
Free Cash Flow	-14.37M	-12.59M	-6.56M	-3.73M	-3.77M	-3.55M
Operating Cash Flow	-14.32M	-12.49M	-6.56M	-3.73M	-3.77M	-3.50M
Investing Cash Flow	-42.00K	-104.00K	0.00	1.00K	-1.00K	-53.00K
Financing Cash Flow	23.72M	13.74M	8.73M	0.00	0.00	13.01M

GlucoTrack Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.87
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GCTK, the sentiment is Negative. The current price of 3.87 is below the 20-day moving average (MA) of 4.21, below the 50-day MA of 5.11, and below the 200-day MA of 6.82, indicating a bearish trend. The MACD of -0.46 indicates Negative momentum. The RSI at 32.93 is Neutral, neither overbought nor oversold. The STOCH value of 53.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GCTK.

GlucoTrack Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EKSO	53 Neutral	$29.79M	-1.48	-85.01%	―	-16.59%	43.20%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FEMY	45 Neutral	$35.39M	-0.81	-376.23%	―	63.53%	12.49%
GCTK	42 Neutral	$3.48M	>-0.01	―	―	―	60.83%
WOK	41 Neutral	$179.60K	―	―	―	―	―

GlucoTrack Corporate Events

GlucoTrack strengthens capital position with new private placement

On December 29, 2025, Glucotrack, Inc. entered into a securities purchase agreement with a single institutional investor for a private placement of pre-funded warrants and common warrants (or common stock equivalents) priced at-the-market under Nasdaq rules, raising approximately $4.0 million in gross proceeds at an effective combined price of $3.87 per share and warrant, with closing occurring on December 31, 2025. The financing, conducted through Curvature Securities LLC as sole placement agent, includes lock-up commitments from officers and directors, ownership caps on warrant exercises, restrictions on additional equity issuance and variable-rate financings for defined periods, and a registration rights framework that will require Glucotrack to register the resale of the underlying securities, collectively reinforcing its near-term capital position for working capital and general corporate purposes while constraining dilution pathways and shaping its funding strategy over the next year.

The most recent analyst rating on (GCTK) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on GlucoTrack stock, see the GCTK Stock Forecast page.

GlucoTrack Issues Investor Presentation Under Regulation FD

On December 29, 2025, GlucoTrack, Inc., a Delaware corporation, issued an investor presentation to its shareholders and the broader market. The materials, which were provided as an investor update rather than a formal securities filing, were explicitly designated as not being subject to the liability provisions applicable to documents deemed filed under the Securities Exchange Act of 1934, underscoring that the presentation serves primarily as informational disclosure for investors rather than a binding regulatory submission.

GlucoTrack Announces Special Shareholders Meeting for Equity Deal

On November 3, 2025, Glucotrack, Inc. announced the reconvening of a Special Meeting of Shareholders on November 7, 2025, to vote on an Equity Purchase Agreement with Sixth Borough Capital Fund. This agreement, compliant with NASDAQ Listing Rule 5635(d), allows the issuance of more than 20% of the company’s common stock, potentially raising $20 million. The company urges all eligible shareholders to vote promptly to ensure their shares are represented, emphasizing the importance of participation in shaping the company’s financial future.

GlucoTrack Appoints Dr. Usman Latif to Advisory Team

On October 29, 2025, Glucotrack announced the appointment of Dr. Usman Latif to its clinical advisory team to enhance its strategy for integrated glucose monitoring applications. This move is part of Glucotrack’s efforts to integrate continuous glucose monitoring into spinal cord stimulation therapies for patients with Painful Diabetic Neuropathy, following their successful preclinical study on epidural glucose monitoring.

GlucoTrack Announces Special Shareholder Meeting for Equity Vote

On October 28, 2025, Glucotrack, Inc. announced a Special Meeting of Shareholders scheduled for October 31, 2025, to vote on an Equity Purchase Agreement with Sixth Borough Capital Fund. The company emphasized the importance of shareholder participation and provided details on how to vote, encouraging shareholders to ensure their shares are represented. The Board of Directors recommended voting in favor of all proposals, highlighting the significance of the meeting for the company’s future operations and strategic direction.